Lantern Pharma Stock Falls 10% After FDA Clears Investigational New Drug Application For STAR-001

Shares of Lantern Pharma fell about 10% on Friday morning after the company and its subsidiary Starlight Therapeutics announced the U.S. FDA has cleared an Investigational New Drug (IND) application. The IND clearance is a regulatory positive that enables clinical development, but the market reaction was sharply negative, suggesting investor concern or positioning unrelated to the announcement.

Analysis

Shares of Lantern Pharma fell about 10% on Friday morning after the company and its subsidiary Starlight Therapeutics announced the U.S. FDA has cleared an Investigational New Drug (IND) application. The IND clearance is a regulatory positive that enables clinical development, but the market reaction was sharply negative, suggesting investor concern or positioning unrelated to the announcement.